Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous hematopoietic stem cell transplantation
- Development stage
- Unknown
- Lead developer
- Northwestern University
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous hematopoietic stem cell transplantation (AHSCT) is an intensive immune-resetting therapy developed for patients with highly active relapsing-remitting multiple sclerosis (RRMS). The procedure involves the mobilization of a patient's own hematopoietic stem cells from the bone marrow into the peripheral blood using granulocyte colony-stimulating factor (G-CSF), followed by their collection and cryopreservation. The patient then undergoes a conditioning regimen—at Northwestern University, this typically consists of high-dose cyclophosphamide and rabbit anti-thymocyte globulin (rATG)—to deplete the existing autoreactive immune system. The harvested stem cells are subsequently re-infused intravenously to reconstitute a new, self-tolerant immune repertoire. The Phase 3 "MOST" trial specifically investigates whether the addition of Intravenous Immunoglobulin (IVIg) to the standard conditioning regimen can improve clinical outcomes and safety by modulating the immune response during the recovery phase.
- Other names
- Autologous peripheral blood hematopoietic stem cell transplantMOST: IVIg in HSCT for Multiple Sclerosis
Beyond the preview
Go deeper on Autologous hematopoietic stem cell transplantation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Autologous hematopoietic stem cell transplantation.